The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Cited by
Sorted by citations
Items 501–600 of 1,001
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Pravin, N., & Jóźwiak, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116837 · Cited by 29
Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2
Scott, D. C., Dharuman, S., Griffith, E. C., Chai, S. C., Ronnebaum, J., King, M. T., Tangallapally, R. P., Lee, C., Gee, C. T., Yang, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52966-3 · Cited by 29
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Li, Y., Wu, Y., Gao, S., Sun, T., & Jiang, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.076 · Cited by 29
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 29
Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?
Powell, M., Blaskovich, M. A. T., & Hansford, K. A. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00203 · Cited by 29
Tong, J., Tan, X., Risnik, D., Gao, M., Song, X., Ermine, K., Shen, L., Wang, S., Yu, J., & Zhang, L. (2021) · Oncogene · doi:10.1038/s41388-021-02041-8 · Cited by 29
Natural product-based PROteolysis TArgeting Chimeras (PROTACs)
Liu, M., Martyn, A. P., & Quinn, R. J. (2022) · Natural Product Reports · doi:10.1039/d2np00038e · Cited by 29
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 31
Targeted therapy for fusion-driven high-risk acute leukemia
Pikman, Y., & Stegmaier, K. (2018) · Blood · doi:10.1182/blood-2018-04-784157 · Cited by 29
Spy vs. spy: selecting the best reporter for 19 F NMR competition experiments
Castro, G. V., & Ciulli, A. (2019) · Chemical Communications · doi:10.1039/c8cc09790a · Cited by 29
Self-citationThe application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29
Abbas, A., & Ye, F. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134293 · Cited by 29
Brd4‐Brd2 isoform switching coordinates pluripotent exit and Smad2‐dependent lineage specification
Fernández-Alonso, R., Davidson, L., Hukelmann, J. L., Zengerle, M., Prescott, A. R., Lamond, A. I., Ciulli, A., Sapkota, G. P., & Findlay, G. M. (2017) · EMBO Reports · doi:10.15252/embr.201643534 · Cited by 28
Self-citationStructure-Guided Design of a “Bump-and-Hole” Bromodomain-Based Degradation Tag
Nowak, R. P., Xiong, Y., Kirmani, N., Kalabathula, J., Donovan, K. A., Eleuteri, N. A., Yuan, J., & Fischer, E. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00958 · Cited by 28
Huang, Y., Yokoe, H., Kaiho-Soma, A., Takahashi, K., Hirasawa, Y., Morita, H., Ohtake, F., & Kanoh, N. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00490 · Cited by 28
Therapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 28
Tang, R., Wang, Z., Xiang, S., Wang, L., Yu, Y., Wang, Q., Deng, Q., Hou, T., & Sun, H. (2023) · JACS Au · doi:10.1021/jacsau.3c00195 · Cited by 28
The size matters? A computational tool to design bivalent ligands
Pérez‐Benito, L., Henry, A., Matsoukas, M., Lopez, L., Pulido, D., Royo, M., Cordomí, A., Tresadern, G., & Pardo, L. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty422 · Cited by 28
Chernobrovkin, A. L., Cázares-Körner, C., Friman, T., Caballero, I. M., Amadio, D., & Molina, D. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220984372 · Cited by 28
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 28
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
Hayhow, T. G., Williamson, B., Lawson, M., Cureton, N., Braybrooke, E. L., Campbell, A., Carbajo, R. J., Cheraghchi-Bashi, A., Chiarparin, E., Diène, C. R., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06238-x · Cited by 27
Worldwide Protein Data Bank validation information: usage and trends
Smart, O. S., Horský, V., Gore, S. P., Vařeková, R. S., Bendová, V., Kleywegt, G. J., & Velankar, S. S. (2018) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318003303 · Cited by 27
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
Zhang, P., Zhang, X., Liu, X., Khan, S. U., Zhou, D., & Zheng, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00017 · Cited by 27
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Yuan, M., Chu, Y., & Duan, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691093 · Cited by 27
Recent advances in induced proximity modalities
Ng, C. S. C., & Banik, S. M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102107 · Cited by 27
Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
Diaz, S., Wang, K., Sjögren, B., & Liu, X. (2022) · Biomolecules · doi:10.3390/biom12030416 · Cited by 27
Heitel, P. (2023) · Molecules · doi:10.3390/molecules28020690 · Cited by 27
Xu, Y., Yuan, Y., Fu, D., Fu, Y., Zhou, S., Yang, W., Wang, X., Li, G., Dong, J., Du, F., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117299 · Cited by 27
Reversible Assembly of Proteolysis Targeting Chimeras
Gui, W., Giardina, S. F., Balzarini, M., Barany, F., & Kodadek, T. J. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00199 · Cited by 27
Xie, L., & Xie, L. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010974 · Cited by 26
Xu, K., Wang, Z., Xiang, S., Tang, R., Deng, Q., Ge, J., Jiang, Z., Yang, K., Hou, T., & Sun, H. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01227 · Cited by 26
Shaik, S., Gayam, P. K. R., Chaudhary, M., Singh, G., & Pai, A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107868 · Cited by 26
Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs
Li, C., Chen, Y., Huang, W., Qiu, Y., Huang, S.-J., Zhou, Y., Zhou, F., Xu, J., Ren, X., Zhang, J., et al. (2024) · JACS Au · doi:10.1021/jacsau.4c00831 · Cited by 27
Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine
Engelberg, I. A., Foley, C. A., James, L. I., & Frye, S. V. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.002 · Cited by 26
ELIOT : A platform to navigate the E3 pocketome and aid the design of new PROTACs
Palomba, T., Baroni, M., Cross, S., Cruciani, G., & Siragusa, L. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14123 · Cited by 26
Weiss, D. R., Bortolato, A., Sun, Y., Cai, X., Lai, C., Guo, S., Shi, L., & Shanmugasundaram, V. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01386 · Cited by 26
Wu, Y., Wu, M., Zheng, X., Yu, H., Mao, X., Jin, Y., Wang, Y., Pang, A., Zhang, J., Zeng, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106952 · Cited by 26
Bao, S.-M., Hu, Q., Yang, W.-T., Wang, Y., Tong, Y.-P., & Bao, W.-D. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190313161009 · Cited by 26
Bayesian optimization for ternary complex prediction (BOTCP)
Rao, A., Tunjic, T. M., Brunsteiner, M., Müller, M., Fooladi, H., Gasbarri, C., & Weber, N. (2023) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2023.100072 · Cited by 25
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
He, Y., Zhu, C., Peng, L., Chen, Y., Zhang, Y., Zheng, Y., & Diao, X. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101175 · Cited by 25
E3 ubiquitin ligases and their therapeutic potential in disease Management
Madhukar, G., Haque, M. A., Khan, S., Kim, J.-J., & Danishuddin (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116875 · Cited by 26
Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation
Li, Y., Bao, K., Sun, J., Ge, R., Zhang, Q., Zhang, B., Yan, X., Li, J., Shi, F., Zhang, M., et al. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01537-1 · Cited by 25
Accurate PROTAC-targeted degradation prediction with DegradeMaster
Liu, J., Roy, M. J., Isbel, L., & Li, F. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf191 · Cited by 25
Estimating the cooperativity of PROTAC-induced ternary complexes using 19 F NMR displacement assay
Castro, G. V., & Ciulli, A. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00215e · Cited by 25
Self-citationHarnessing PROTAC technology to combat stress hormone receptor activation
Gazorpak, M., Hugentobler, K. M., Paul, D., Germain, P., Kretschmer, M., Ivanova, I., Frei, S., Mathis, K. H., Rudolf, R., Barrenechea, S. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44031-2 · Cited by 25
Structural Basis of Conformational Dynamics in the PROTAC‐Induced Protein Degradation
Zhao, H. (2024) · ChemMedChem · doi:10.1002/cmdc.202400171 · Cited by 25
Liver-targeting chimeras as a potential modality for the treatment of liver diseases
Chen, C., Pan, Y., Yang, X., Li, H., Cai, X., He, S., Wang, Q., Yang, Y., Zheng, R., Li, H., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.044 · Cited by 25
In silico modeling of targeted protein degradation
Lv, W., Jia, X., Tang, B., Ma, C., Fan, X., Jin, X., Niu, Z., & Han, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117432 · Cited by 27
The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer
Minervini, G., Pennuto, M., & Tosatto, S. C. E. (2020) · Open Biology · doi:10.1098/rsob.200109 · Cited by 25
Analyzing the Linker Structure of PROTACs throughout the Induction Process: Computational Insights
Li, Y., Zhang, X., Xie, J., Meng, D., Liu, M., Chang, Y., Feng, G., Jiang, J., & Deng, P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02637 · Cited by 24
Yang, Z., Chen, M., Ge, R., Zhou, P., Pan, W., Song, J., Ma, S., Chen, S., Xu, C., Zhou, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57823-5 · Cited by 24
Advancing Design Strategy of PROTACs for Cancer Therapy
Luo, H., Tian, Y., Abdullah, R., Zhang, B., Ma, Y., & Zhang, G. (2025) · MedComm · doi:10.1002/mco2.70258 · Cited by 24
Pan, M., Yang, C., Fu, Z., Yang, Y., Zhuo, Y., Hou, H., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202501384 · Cited by 24
PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age
Cai, J., Chen, C., Wang, J., Zhang, X., Cui, Y., Zhu, Q., & Sun, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1676414 · Cited by 24
Ma, K., Han, X.-X., Han, X., & Zhou, S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308075 · Cited by 24
Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 26
Self-citationGuo, L., Liu, J., Nie, X., Wang, T., Ma, Z., Yin, D., & Tang, W. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128982 · Cited by 24
Advances of bioorthogonal coupling reactions in drug development
Zhan, F., Zhu, J., Xie, S., Xu, J., & Xu, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115338 · Cited by 24
PROTAC chemical probes for histone deacetylase enzymes
Patel, U., Smalley, J. P., & Hodgkinson, J. T. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00105a · Cited by 25
Antermite, D., Friis, S. D., Johansson, J. R., Putra, O. D., Ackermann, L., & Johansson, M. J. (2023) · Nature Communications · doi:10.1038/s41467-023-43789-9 · Cited by 24
Kumar, H., & Sobhia, M. E. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00189 · Cited by 24
Yue, J., Peng, B., Chen, Y., Jin, J., Zhao, X., Shen, C., Ji, X., Hsieh, C., Song, J., Hou, T., et al. (2024) · Chemical Science · doi:10.1039/d4sc03744h · Cited by 25
Arthur, R., Valle‐Argos, B., Steele, A. J., & Packham, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00009 · Cited by 24
Ma, N., Bhattacharya, S., Muk, S., Jandová, Z., Schmalhorst, P. S., Ghosh, S., Le, K., Diers, E., Trainor, N. B., Farnaby, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63713-7 · Cited by 23
Self-citationDevelopments of PROTACs technology in immune-related diseases
Wang, C., Zhang, Y., Deng, J., Liang, B., & Xing, D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115127 · Cited by 23
Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer
Ghosh, A., Himaja, A., Biswas, S., Kulkarni, O. P., & Ghosh, B. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00610 · Cited by 23
Xu, L., Li, P., Hao, X., Lu, Y., Liu, M., Song, W., Shan, L., Yu, J., Ding, H., Chen, S., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00742-6 · Cited by 23
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6
Eynde, J. J. V., Mangoni, A. A., Rautio, J., Leprince, J., Azuma, Y., García‐Sosa, A. T., Hulme, C., Jampílek, J., Karaman, R., Li, W., et al. (2019) · Molecules · doi:10.3390/molecules25010119 · Cited by 23
Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22
Cellular parameters shaping pathways of targeted protein degradation
Cardno, A., Kennedy, B., & Lindon, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08104-w · Cited by 22
Manda, S., Lee, N. K., Oh, D., & Lee, J. (2020) · Molecules · doi:10.3390/molecules25081948 · Cited by 22
Lin, W., & Chen, T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00032 · Cited by 22
Wang, C., Zhang, Y., Zhang, T., Shi, L., Geng, Z., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2076675 · Cited by 22
Distinct Responses to Pathogenic and Symbionic Microorganisms: The Role of Plant Immunity
Ji, L., Yang, X., & Qi, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810427 · Cited by 22
Exploring PROTAC Cooperativity with Coarse-Grained Alchemical Methods
Mai, H., Zimmer, M. H., & Miller, T. F. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c05795 · Cited by 22
Computational strategies for PROTAC drug discovery
Wu, J., Wang, W., & Leung, C. (2023) · Acta Materia Medica · doi:10.15212/amm-2022-0041 · Cited by 22
Microscale thermophoresis (MST) and spectral shift (SpS) in drug discovery
Nowak, J. S., Czarna, A., Grudnik, P., Grygier, P., Pustelny, K., Langer, A., & Dubin, G. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117716 · Cited by 22
Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22
BET proteins: Investigating BRDT as a potential target for male contraception
Wisniewski, A. J., & Georg, G. I. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.126958 · Cited by 22
Hügle, M. J., Regenass, P., Warstat, R., Hau, M., Schmidtkunz, K., Lucas, X., Wohlwend, D., Einsle, O., Jung, M., Breit, B., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00478 · Cited by 23
Self-citationStructure driven compound optimization in targeted protein degradation
Leissing, T. M., Luh, L. M., & Cromm, P. M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.005 · Cited by 22
Wu, X., Meng, Y., Liu, L., Gong, G., Zhang, H., Hou, Y., Liu, C., Wu, D., & Qin, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116038 · Cited by 22
Branched ubiquitin code: from basic biology to targeted protein degradation
Ohtake, F. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac002 · Cited by 22
Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Krupa, K., Fudalej, M. M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17152453 · Cited by 21
Lin, C., Shiau, Y., & Lin, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104563 · Cited by 21
RNA‐PROTACs: Degraders of RNA‐Binding Proteins
Ghidini, A., Cléry, A., Halloy, F., Allain, F. H. ‐., & Hall, J. (2020) · Angewandte Chemie · doi:10.1002/ange.202012330 · Cited by 21
Wolska, A., & Smolewski, P. (2022) · Cancers · doi:10.3390/cancers14153778 · Cited by 21
Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader
Divakaran, A., Scholtz, C. R., Zahid, H., Lin, W., Griffith, E. C., Lee, R. E., Jr., Chen, T., Harki, D. A., & Pomerantz, W. C. K. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00300 · Cited by 21
Yang, Z., Ying, Y., Cheng, S., Wu, J., Zhang, Z., Hu, P., Xiong, J., Li, H., Zeng, Q. G., Cai, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00356 · Cited by 21
Chen, Y., Xia, Z., Suwal, U., Rappu, P., Heino, J., Wever, O. D., & Geest, B. G. D. (2024) · Chemical Science · doi:10.1039/d4sc03555k · Cited by 21
Cai, L., Yue, G., Chen, Y., Wang, L., Yao, X., Zou, Q., Fu, X., & Cao, D. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae654 · Cited by 21
Thioamide substitution to probe the hydroxyproline recognition of VHL ligands
Soares, P., Lucas, X., & Ciulli, A. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.034 · Cited by 21
Self-citationRecent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21
Müller, M., Burmeister, A., Skowron, M. A., Stephan, A., Bremmer, F., Wakileh, G. A., Petzsch, P., Köhrer, K., Albers, P., & Nettersheim, D. (2022) · Clinical Epigenetics · doi:10.1186/s13148-021-01223-1 · Cited by 21
Pinch, B. J., Buckley, D. L., Gleim, S., Brittain, S. M., Tandeske, L., D'Alessandro, P. L., Hauseman, Z. J., Lipps, J., Xu, L., Harvey, E. P., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.08.007 · Cited by 20
Lu, Y., Yan, Z., Sun, J., Wang, C., Xu, L., Lyu, X., Wang, X., Lou, J., Huang, H., Meng, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02884 · Cited by 20
He, X., Zeng, S., Wen, Y., Yang, T., Huang, C., Li, Y.-F., Zhang, Z., Ding, K., Liu, T., Tan, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18083 · Cited by 20
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells
Mahan, S. D., Riching, K. M., Urh, M., & Daniels, D. L. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_8 · Cited by 20
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
Kumar, A., Emdad, L., Fisher, P. B., & Das, S. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.01.001 · Cited by 20
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
